Studies have shown that the AMPK pathway is the most important and closely related to SGLT2 inhibitors in diabetic cardiomyopathy, and AMPK activation may be a key point in inhibition of the anti-inflammatory effects of SGLT2 inhibitors (Ye et al., 2017; Uthman et al., 2018; Aragon-Herrera et al., 2019; Chen et al., 2020). Here, SLC5A2 is linked to diabetic cardiomyopathy.